Table 1.
Oral doxycycline pharmacokinetics in dogs
| Source | No. of subjects | Dose (mg/kg) | Mean ± SDa |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| t1/2 (h) | kel (h−1) | Vd/F (liters/kg) | CL/F (liters/kg/h) | AUC (μg·h/ml) | Cmax (μg/ml) | Absorption t1/2 (h) | Tmax (h) | F (%) | |||
| van Gool et al. (11) | 4 | 10 | 8.34 ± 2.77 | 0.0831 ± 0.0277 | 1.28 ± 0.5 | 0.1 ± 0.02 | NR | 4.03 ± 1.25 | 0.87 ± 0.4 | 3.04 ± 1.15 | 57.3 ± 17.2 |
| Gutierrez et al. (10) | 12 | 10 | 5.59 ± 0.03 | 0.124 ± 0.0007 | 1.49 ± 0.27 | 0.137 ± 0.012 | 72.89 ± 6.3 | 5.58 ± 0.5 | 1.49 ± 0.07 | 3.88 ± 0.4 | 74.88 |
| Dominguez et al. (presented at the American Academy of Veterinary Pharmacology and Therapeutics 18th Biennial Symposium) | 5 | 10 | NR | NR | NR | 0.215 ± 0.065 | NR | NR | NR | NR | NR |
| Rogar (unpublished data) | 6 | 5.023 | 29.496 ± 6.15 | 0.0235 ± 0.0049 | 2.299 ± 1.333 | 0.0676 ± 0.035 | 92.962 ± 53.89 | 3.968 ± 3.904 | NR | 4.125 ± 2.326 | 53.36 ± 28.57 |
| Overall mean ± SD | 14.475 ± 3.066 | 0.077 ± 0.015 | 1.690 ± 0.559 | 0.102 ± 0.012 | 82.926 ± 33.651 | 4.526 ± 1.789 | 1.180 ± 0.233 | 3.682 ± 0.971 | 61.847 ± 8.040 | ||
| Weighted mean ± SD | 27 | 12.61 ± 11.10 | 1.67 ± 0.81 | 0.131 ± 0.061 | |||||||
a
t1/2, terminal half-life; kel, terminal rate constant; Vd/F, apparent volume of distribution per fraction absorbed; CL/F, systemic clearance per fraction absorbed; AUC, area under the curve; Cmax, maximal (peak) plasma concentration; absorption t1/2, half-life for oral absorption; Tmax, time to peak concentration; F, fraction of oral dose absorbed; NR, not reported in the study. Weighted means and standard deviations (described in more detail in the text) account for weighted differences in the numbers of subjects per study and within-study variations. Weighted means were calculated only for parameters that were necessary for Monte Carlo simulations.